Cargando…

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Terragna, Carolina, Remondini, Daniel, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Patriarca, Francesca, Pezzi, Annalisa, Levi, Giuseppe, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, Tacchetti, Paola, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, Santacroce, Barbara, Borsi, Enrica, Brioli, Annamaria, Marzocchi, Giulia, Castellani, Gastone, Martinelli, Giovanni, Palumbo, Antonio, Cavo, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891075/
https://www.ncbi.nlm.nih.gov/pubmed/26575327
http://dx.doi.org/10.18632/oncotarget.5718